NASDAQ: AVROAvrobio Inc Stock
$1.48+0.04 (+2.78%)
Updated May 31, 2024
AVRO Price
$1.48
Fair Value Price
$2.19
Market Cap
$66.44M
52 Week Low
$0.88
52 Week High
$1.65
P/E
2.11x
P/B
0.75x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$30.31M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$50M
Beta
1.19
Next Earnings
Jun 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AVRO Overview
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AVRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVRO ($1.48) is undervalued by 32.3% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AVRO ($1.48) is significantly undervalued by 32.3% relative to our estimate of its Fair Value price of $2.19 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AVRO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more AVRO due diligence checks available for Premium users.
Be the first to know about important AVRO news, forecast changes, insider trades & much more!
AVRO News
Valuation
AVRO fair value
Fair Value of AVRO stock based on Discounted Cash Flow (DCF)
Price
$1.48
Fair Value
$2.19
Undervalued by
32.30%
AVRO ($1.48) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVRO ($1.48) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
2.11x
Industry
-14.17x
Market
28.44x
AVRO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AVRO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
AVRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.75x
Industry
6.04x
AVRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AVRO's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.8M
Profit Margin
0%
AVRO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$92.3M
Liabilities
$3.5M
Debt to equity
0.04
AVRO's short-term assets ($91.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVRO's short-term assets ($91.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVRO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.6M
Investing
$0.0
Financing
$30.0k
AVRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AVRO vs Biotech Stocks
Avrobio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.